BOUT ETF
CapForce IBD Breakout Opportunities ETF
BOUT ETF Overview
BOUT ETF (CapForce IBD Breakout Opportunities ETF) is managed by Capital-FORCE ETF with $15.7M in net assets. BOUT expense ratio is 0.80%, holding 48 positions across sectors including Financials, Health Care, Consumer Discretionary. Inception date: 2018-09-12.
BOUT performance shows a YTD return of 27.03%. The 1-year return is 23.71% and the 5-year return is 6.96%. BOUT dividend yield stands at 0.27%, paid annually.
BOUT top holdings include Enliven Therapeutics Inc (7.6%), Glaukos Corp. (7.1%), Bicara Therapeutics, Inc. (7.0%), US Bancorp (7.0%), Liquidia Technologies Inc (6.3%). Go to all BOUT holdings, BOUT sectors, or BOUT dividends.
BOUT can be compared against other funds. Use BOUT overlap to find shared positions, or BOUT vs another fund for a side-by-side view. BOUT alternatives are available via the screener, along with tax-loss harvesting opportunities.